摘要
本文作者主持完成的国产HeartCon型植入式左心室辅助装置(LVAD)治疗终末期心力衰竭(ESHF)的临床试验和拓展试验涵盖了11家医疗单位治疗的62例受试者。研究结果证明了该型LVAD治疗ESHF的安全性和有效性。在临床实践中,我们既验证了一些国际通识,又产生了一些有别于国际惯例、被反复实践证明更合理的观点和方法。期望通过分享我们的经验和思辨,为同行提供参考和借鉴。
The author,as a coordinating investigator,jointly with the other ten PIs conducted a 62-case multicenter clinical trial of a domestic HeartCon implantable left ventricular assist device(LVAD)for the treatment of end-stage heart failure(ESHF),the results of which demonstrated the safety and efficacy of the device.In the clinical practice,we have not only validated the international general knowledge,but also created some ideas and methods that are different from the international traditional practice and has been proved to be more reasonable by repeated practice.We hereby would like to share our experience and speculation,so as to provide the reference for the colleagues.
作者
刘晓程
Liu Xiaocheng(Department of Cardiovascular Surgery,TEDA International Cardiovascular Hospital,Tianjin 300457,China)
出处
《中华胸心血管外科杂志》
CSCD
北大核心
2023年第5期283-290,共8页
Chinese Journal of Thoracic and Cardiovascular Surgery